The query "Januvia SGLT2" likely stems from a misunderstanding, as Januvia (sitagliptin) is not an SGLT2 inhibitor. Januvia belongs to a class of drugs called DPP-4 inhibitors. SGLT2 inhibitors are a separate class of diabetes medications.
What are DPP-4 Inhibitors like Januvia?
DPP-4 inhibitors, including Januvia, work by increasing the levels of incretin hormones. These hormones help regulate blood sugar by stimulating the pancreas to release insulin and reducing the amount of glucose produced by the liver. They are used to improve glycemic control in adults with type 2 diabetes [1].
What are SGLT2 Inhibitors?
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are another class of oral diabetes medications. They work differently from DPP-4 inhibitors by blocking the reabsorption of glucose in the kidneys, causing excess glucose to be excreted in the urine [2]. Examples of SGLT2 inhibitors include empagliflozin, canagliflozin, and dapagliflozin.
How do DPP-4 Inhibitors and SGLT2 Inhibitors Differ?
The primary difference lies in their mechanism of action and the pathways they target to lower blood glucose. DPP-4 inhibitors enhance incretin hormone function, while SGLT2 inhibitors act on the kidneys to increase glucose excretion [1, 2]. This distinction means they can sometimes be used in combination to achieve better blood sugar control.
When Does Januvia's Patent Protection End?
The original patent for sitagliptin, the active ingredient in Januvia, expired on a specific date. DrugPatentWatch.com tracks patent information and can provide details on patent expiry and any related exclusivities for Januvia and its generic versions [3].
Are There Generic Versions of Januvia Available?
Following patent expiry, generic versions of Januvia become available. These generics contain the same active ingredient and are considered therapeutically equivalent to the branded drug, often at a lower cost [3].
Can Januvia Be Used With SGLT2 Inhibitors?
Yes, Januvia (a DPP-4 inhibitor) can be prescribed alongside SGLT2 inhibitors as part of a comprehensive treatment plan for type 2 diabetes. This combination therapy may be beneficial for patients who do not achieve their target blood glucose levels with a single medication or who may benefit from the complementary mechanisms of action [1, 2].
Sources:
[1] https://www.drugpatentwatch.com/blog/understanding-different-types-of-diabetes-medications-dpp-4-inhibitors-vs-sglt2-inhibitors
[2] https://www.drugpatentwatch.com/blog/understanding-different-types-of-diabetes-medications-dpp-4-inhibitors-vs-sglt2-inhibitors
[3] https://www.drugpatentwatch.com/drug/januvia